AIM ImmunoTech Inc ARS, filed Sep 30, 2026

AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. is focusing Ampligen development on late-stage pancreatic cancer; patients have enrolled in the DURIPANC Phase 2 study, and the PPD clinical research business of Thermo Fisher Scientific will design an anticipated Phase 3 trial. AI summary